Arto Puranen1,2, Marjaana Koponen3,4, Antti Tanskanen5,6, Jari Tiihonen5,6,7, Heidi Taipale5,3,6. 1. Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland. avpurane@student.uef.fi. 2. School of Pharmacy, University of Eastern Finland, Kuopio, Finland. avpurane@student.uef.fi. 3. School of Pharmacy, University of Eastern Finland, Kuopio, Finland. 4. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. 5. Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland. 6. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. 7. Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden.
Abstract
PURPOSE: Antipsychotics are first-line treatment of schizophrenia. They are often accompanied by adjunctive treatments, such as antidepressant (AD) or mood stabilizer (MS), although there is only limited information of their use in first-episode schizophrenia. This study aimed to investigate AD and MS initiation and factors associated with initiation in persons with first-episode schizophrenia. METHODS: Register-based data was utilized to identify persons who received inpatient care due to schizophrenia during 1996-2014 in Finland and who did not use AD or MS at the time of first inpatient care diagnosis of schizophrenia (N = 7667, mean age 40.2, SD 18.2). Drug purchase data (1995-2017) was obtained from the National Prescription register and modelled with PRE2DUP method. Initiations of AD and MS use were followed up 3 years from first schizophrenia diagnoses. Cox proportional hazard models were used to investigate factors associated with AD or MS initiation. RESULTS: Among persons with first-episode schizophrenia, 35.4% initiated AD and 14.1% initiated MS use within three years from diagnoses. Female gender, younger age, and benzodiazepine use were associated with higher risk of AD and MS initiation. The number of previous psychoses was associated with decreased risk of AD and increased risk of MS initiation. CONCLUSION: Clinical guidelines rarely recommend the use of AD or MS as adjunctive treatment in persons with schizophrenia. However, this population is often treated with AD or MS. More studies are needed to evaluate benefits and risks of these medications as adjunctive treatment of schizophrenia.
PURPOSE: Antipsychotics are first-line treatment of schizophrenia. They are often accompanied by adjunctive treatments, such as antidepressant (AD) or mood stabilizer (MS), although there is only limited information of their use in first-episode schizophrenia. This study aimed to investigate AD and MS initiation and factors associated with initiation in persons with first-episode schizophrenia. METHODS: Register-based data was utilized to identify persons who received inpatient care due to schizophrenia during 1996-2014 in Finland and who did not use AD or MS at the time of first inpatient care diagnosis of schizophrenia (N = 7667, mean age 40.2, SD 18.2). Drug purchase data (1995-2017) was obtained from the National Prescription register and modelled with PRE2DUP method. Initiations of AD and MS use were followed up 3 years from first schizophrenia diagnoses. Cox proportional hazard models were used to investigate factors associated with AD or MS initiation. RESULTS: Among persons with first-episode schizophrenia, 35.4% initiated AD and 14.1% initiated MS use within three years from diagnoses. Female gender, younger age, and benzodiazepine use were associated with higher risk of AD and MS initiation. The number of previous psychoses was associated with decreased risk of AD and increased risk of MS initiation. CONCLUSION: Clinical guidelines rarely recommend the use of AD or MS as adjunctive treatment in persons with schizophrenia. However, this population is often treated with AD or MS. More studies are needed to evaluate benefits and risks of these medications as adjunctive treatment of schizophrenia.
Authors: M Isohanni; T Mäkikyrö; J Moring; P Räsänen; H Hakko; U Partanen; M Koiranen; P Jones Journal: Soc Psychiatry Psychiatr Epidemiol Date: 1997-07 Impact factor: 4.328
Authors: Jari Tiihonen; Ellenor Mittendorfer-Rutz; Maila Majak; Juha Mehtälä; Fabian Hoti; Erik Jedenius; Dana Enkusson; Amy Leval; Jan Sermon; Antti Tanskanen; Heidi Taipale Journal: JAMA Psychiatry Date: 2017-07-01 Impact factor: 21.596
Authors: Bartosz Helfer; Myrto T Samara; Maximilian Huhn; Elisabeth Klupp; Claudia Leucht; Yikang Zhu; Rolf R Engel; Stefan Leucht Journal: Am J Psychiatry Date: 2016-06-10 Impact factor: 18.112
Authors: Maria F Strømme; Liv S Mellesdal; Christoffer A Bartz-Johannesen; Rune A Kroken; Marianne L Krogenes; Lars Mehlum; Erik Johnsen Journal: J Clin Psychopharmacol Date: 2022 Jan-Feb 01 Impact factor: 3.153